On November 4, 2021 Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, reported that two abstracts have been accepted for a poster presentation and an oral session at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held in person in Atlanta, Georgia and virtually from December 11-14, 2021 (Press release, Celyad, NOV 4, 2021, View Source [SID1234594508]). The poster will focus on the Company’s shRNA-based anti-BCMA allogeneic CAR T candidate CYAD-211 for the treatment of relapsed/refractory (r/r) multiple myeloma (r/r MM). The oral session will focus on the Company’s autologous NKG2D receptor-based CAR T candidate CYAD-02 for the treatment of r/r acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In addition, the abstracts will be published online in the November supplemental issue of peer-reviewed journal Blood.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ASH 2021 Presentation Details:
The following abstracts published today are now available on the ASH (Free ASH Whitepaper) conference website. Following their presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.
Publication #2817: IMMUNICY-1: Targeting BCMA with CYAD-211 to Establish Proof Of Concept of An shRNA-based Allogeneic CAR T Cell Therapy Platform
Session Name: 704. Cellular Immunotherapies: Clinical: Poster II – Poster presentation
Date: Sunday, December 12, 2021, from 6:00 p.m. to 8:00 p.m. ET
Location: Georgia World Congress Center, Hall B5
Publication #408: Co-expression of an shRNA Targeting MICA/MICB Improves the Clinical Activity of a NKG2D-based CAR T In Patients with Relapsed / Refractory AML/MDS
Session Name: 703. Cellular Immunotherapies: Basic and Translational II – Oral session
Date: Sunday, December 12, 2021
Presentation Time: 10:45 a.m. ET
Location: Georgia World Congress Center, Room B405-407